Maple Securities Usa Inc Exits Position in Pfizer (PFE)

Pfizer (PFE) : Maple Securities Usa Inc has sold out all of its stake in Pfizer during the most recent quarter, according to the disclosure filed by the company on Apr 13, 2016 with the SEC. The investment management company has sold out 37,579 shares of Pfizer which is valued at $1,221,318.

Pfizer opened for trading at $32.3 and hit $32.86 on the upside on Monday, eventually ending the session at $32.61, with a gain of 0.34% or 0.11 points. The heightened volatility saw the trading volume jump to 3,69,99,336 shares. Company has a market cap of $201,665 M.

Other Hedge Funds, Including , 1st Global Advisors boosted its stake in PFE in the latest quarter, The investment management firm added 7,473 additional shares and now holds a total of 108,663 shares of Pfizer which is valued at $3,531,548. Pfizer makes up approx 0.50% of 1st Global Advisors’s portfolio.Mai Capital Management boosted its stake in PFE in the latest quarter, The investment management firm added 8,686 additional shares and now holds a total of 178,343 shares of Pfizer which is valued at $5,687,358. Pfizer makes up approx 0.47% of Mai Capital Management’s portfolio.Ct Financial Advisors reduced its stake in PFE by selling 1,552 shares or 7.08% in the most recent quarter. The Hedge Fund company now holds 20,358 shares of PFE which is valued at $649,217. Pfizer makes up approx 0.38% of Ct Financial Advisors’s portfolio.Renaissance Investment Group reduced its stake in PFE by selling 632 shares or 1.63% in the most recent quarter. The Hedge Fund company now holds 38,200 shares of PFE which is valued at $1,147,528. Pfizer makes up approx 0.57% of Renaissance Investment Group’s portfolio.

On the company’s financial health, Pfizer reported $0.53 EPS for the quarter, beating the analyst consensus estimate by $ 0.17 according to the earnings call on Feb 2, 2016. Analyst had a consensus of $0.36. The company had revenue of $14047.00 million for the quarter, compared to analysts expectations of $13595.19 million. The company’s revenue was up 7.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.54 EPS.

Many Wall Street Analysts have commented on Pfizer. Goldman Resumed Pfizer on Apr 18, 2016 to “Neutral”, Price Target of the shares are set at $35.JP Morgan Resumed Pfizer on Apr 7, 2016 to “Overweight”, Price Target of the shares are set at $38.Morgan Stanley Resumed Pfizer on Apr 7, 2016 to “Equal-Weight”, Price Target of the shares are set at $35.

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.

Leave a Reply

Pfizer - Is it time to Sell?

Top Brokerage Firms are advising their investors on Pfizer. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.